Atomo Diagnostics Ltd. (AT1) Price & Analysis

Compare

7 Followers

AT1 Stock Chart & Stats

AU$0.04

>-AU$0.01(-5.00%)

At close: Jan 09 4:00 PM EST

AU$0.04

>-AU$0.01(-5.00%)

Day’s Range― - ―

52-Week RangeAU$0.01 - AU$0.05

Previous CloseN/A

Volume312.94K

Average Volume (3M)1.80M

Market Cap

AU$29.17M

Enterprise ValueAU$26.41M

Total Cash (Recent Filing)AU$3.51M

Total Debt (Recent Filing)AU$754.39K

Price to Earnings (P/E)―

Beta0.48

Next Earnings

Apr 23, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding810,175,300

10 Day Avg. Volume984,499

30 Day Avg. Volume1,797,539

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)1.30

Price to Sales (P/S)2.39

P/FCF Ratio-4.55

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Integrated RDT PlatformAtomo’s integrated blood collection and rapid-test device is a structural competitive asset: it simplifies test kit assembly for partners, creates product stickiness with manufacturers and programs, and can drive recurring device sales and long-term adoption across point-of-care markets.

Low Financial LeverageMinimal leverage provides durable financial flexibility: with very low debt the company can endure operating losses longer, prioritize strategic partnerships or product development, and avoid high interest burdens that would otherwise constrain reinvestment or commercialization efforts.

B2B, Program-aligned Revenue ModelSelling hardware to diagnostic manufacturers and public health programs supports steady, volume-driven revenue when partners scale testing. This B2B model favors contractable, repeatable unit demand tied to program budgets, aiding predictable manufacturing ramps and long-term partner relationships.

Bears Say

Declining Revenue TrendSustained revenue decline reduces operating scale and weakens unit economics: lower volumes hinder fixed-cost absorption, impede margin recovery, reduce bargaining power with suppliers and partners, and make it harder to justify continued investment in product development and commercialization.

Deep And Persistent LossesSevere negative margins indicate ongoing inability to convert sales into sustainable profits. Persistent losses erode equity, limit internal funding for growth, increase reliance on external capital, and can pressure management to cut strategic initiatives or accept dilutive financing over the medium term.

Deteriorating Cash FlowWorsening free cash flow constrains the company’s ability to scale manufacturing, support commercial rollouts, or invest in regulatory approvals without external funding. Continued cash burn raises dilution and refinancing risk, limiting strategic options and partner investment over months.

Atomo Diagnostics Ltd. News

Atomo Diagnostics Targets Growth in Decentralized Rapid Testing Market

Atomo Diagnostics Ltd. ( ($AU:AT1) ) has provided an update. Atomo Diagnostics is sharpening its focus on the...

18d ago

AT1

Atomo Diagnostics Narrows Half-Year Loss as Revenue Edges Higher

Atomo Diagnostics Ltd. ( ($AU:AT1) ) has provided an announcement. Atomo Diagnostics reported a modest 6% rise in...

18d ago

AT1

Atomo Wins A$630,000 Order for Government-Backed HIV Self-Testing Program

The latest update is out from Atomo Diagnostics Ltd. ( ($AU:AT1) ). Atomo Diagnostics has secured a material...

1M ago

AT1

Atomo Wins Second Major Global Fund–Backed Order for HIV Self-Tests

Atomo Diagnostics Ltd. ( ($AU:AT1) ) has shared an announcement. Atomo Diagnostics has secured a A$416,000 purchase order...

1M ago

AT1

Atomo Diagnostics Sets Date for Q2 FY26 Results and Investor Webinar

Atomo Diagnostics Ltd. ( ($AU:AT1) ) has provided an announcement. Atomo Diagnostics has scheduled the release of its...

2M ago

AT1

Atomo Diagnostics Wins Exclusive Global Licence for Rapid Liver Function Test on Pascal Platform

Atomo Diagnostics Ltd. ( ($AU:AT1) ) has shared an announcement. Atomo Diagnostics has secured an exclusive global licence...

2M ago

AT1

Atomo Wins $502,000 HIV Self-Test Order Backed by Global Fund

Atomo Diagnostics Ltd. ( ($AU:AT1) ) just unveiled an announcement. Atomo Diagnostics Limited has secured a material purchase...

2M ago

AT1

Atomo Diagnostics Grants Options to Director Following Shareholder Approval

An announcement from Atomo Diagnostics Ltd. ( ($AU:AT1) ) is now available. Atomo Diagnostics Ltd. announced a change...

3M ago

AT1

Atomo Diagnostics Issues New Equity Securities Under Employee Incentive Scheme

Atomo Diagnostics Ltd. ( ($AU:AT1) ) has provided an announcement. Atomo Diagnostics Ltd. has announced the issuance of...

3M ago

AT1

Atomo Diagnostics Addresses ASX Query on Unusual Trading Activity

Atomo Diagnostics Ltd. ( ($AU:AT1) ) has issued an update. Atomo Diagnostics Ltd. has responded to an ASX...

3M ago

AT1

AT1 FAQ

What was Atomo Diagnostics Ltd.’s price range in the past 12 months?

Atomo Diagnostics Ltd. lowest share price was AU$0.01 and its highest was AU$0.05 in the past 12 months.

What is Atomo Diagnostics Ltd.’s market cap?

Atomo Diagnostics Ltd.’s market cap is AU$29.17M.

When is Atomo Diagnostics Ltd.’s upcoming earnings report date?

Atomo Diagnostics Ltd.’s upcoming earnings report date is Apr 23, 2026 which is in 39 days.

How were Atomo Diagnostics Ltd.’s earnings last quarter?

Atomo Diagnostics Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.

Is Atomo Diagnostics Ltd. overvalued?

According to Wall Street analysts Atomo Diagnostics Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Atomo Diagnostics Ltd. pay dividends?

Atomo Diagnostics Ltd. does not currently pay dividends.

What is Atomo Diagnostics Ltd.’s EPS estimate?

Atomo Diagnostics Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Atomo Diagnostics Ltd. have?

Atomo Diagnostics Ltd. has 810,175,300 shares outstanding.

What happened to Atomo Diagnostics Ltd.’s price movement after its last earnings report?

Atomo Diagnostics Ltd. reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.895%.

Which hedge fund is a major shareholder of Atomo Diagnostics Ltd.?

Currently, no hedge funds are holding shares in AU:AT1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Atomo Diagnostics Ltd. Stock Smart Score

Neutral

Blogger Sentiment

Bullish

AU:AT1 Sentiment 100%
Sector Average ―

Technicals

Fundamentals

Return on Equity

-58.40%

Trailing 12-Months

Asset Growth

2.49%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Atomo Diagnostics Ltd.

Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. It offers rapid diagnostic test devices for COVID-19, HIV screening, pregnancy test, and respiratory test. The company was incorporated in 2010 and is headquartered in Leichhardt, Australia.